| Metric | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥2276.8B | ¥2195.1B | +3.7% |
| Operating Income / Operating Profit | ¥19.2B | ¥20.3B | -5.1% |
| Equity-method Investment Income (Loss) | - | - | - |
| Ordinary Income | ¥22.9B | ¥24.1B | -4.8% |
| Net Income / Net Profit | ¥12.8B | ¥13.7B | -6.4% |
| ROE | 6.1% | 6.7% | - |
For the 9-month cumulative period of FY2026 (ending March 2026), Revenue was ¥2,276.8B (YoY +¥81.7B +3.7%), Operating Income was ¥19.2B (YoY -¥1.0B -5.1%), Ordinary Income was ¥22.9B (YoY -¥1.1B -4.8%), and Net Income attributable to owners of parent was ¥12.8B (YoY -¥0.9B -6.4%). Revenue continued its third consecutive period of growth, but Selling, General and Administrative Expenses increased more than gross profit expansion, resulting in declines below Operating Income. Operating margin was 0.8% (down 0.1pt from 0.9% in the prior year period), and Net margin was 0.6% (flat from 0.6%), remaining at low levels. Progress against full-year forecasts was Revenue 74.7%, Operating Income 109.9%, Ordinary Income 99.7%, and Net Income 98.6%, with Operating Income progressing ahead of the initial plan.
[Revenue] Revenue was ¥2,276.8B (YoY +¥81.7B +3.7%), maintaining a steady growth trend. By segment, the core Medical Devices Sales Business recorded ¥2,229.2B (+3.7%) comprising 97.9% of sales, and the Nursing Care & Welfare Business recorded ¥47.7B (+4.1%) comprising 2.1%. Gross profit was ¥270.9B (YoY +¥9.5B +3.6%) with a gross margin of 11.9% (flat YoY), roughly tracking revenue growth. The revenue increase was mainly driven by resilient demand in the medical device market and accumulation of projects, but price competition and product mix prevented improvement in gross margin.
[Profitability] Against gross profit of ¥270.9B, SG&A was ¥251.6B (YoY +¥10.5B +4.3%), rising faster than gross profit growth (+3.6%) and reversing operating leverage. Major SG&A increases were salaries and allowances ¥102.7B (4.5% of sales) and rent ¥18.8B (0.8% of sales), with higher personnel and rental costs pressuring earnings. As a result, Operating Income was ¥19.2B (YoY -¥1.0B -5.1%) and Operating margin fell to 0.8% (down 0.1pt from 0.9%). Non-operating income of ¥6.0B (including dividend income ¥0.3B, subsidy income ¥1.6B) less non-operating expenses of ¥2.3B (including interest expense ¥1.7B) produced a net +¥3.7B that partially offset operating-stage declines, resulting in Ordinary Income of ¥22.9B (YoY -¥1.1B -4.8%). Extraordinary income of ¥1.2B (gain on sale of investment securities ¥1.2B) less extraordinary losses of ¥0.2B (loss on retirement of fixed assets ¥0.2B, impairment losses ¥0.0B) netted +¥1.1B supporting profit before tax, which was ¥24.0B (YoY -¥0.3B -1.2%). After corporate taxes of ¥11.1B (effective tax rate 46.5%), Net Income was ¥12.8B (YoY -¥0.9B -6.4%), confirming a revenue-up/profit-down trend.
The Medical Devices Sales Business posted Revenue ¥2,229.2B (YoY +3.7%) and Operating Income ¥75.1B (YoY -9.1%), with a margin of 3.4% (down 0.4pt from 3.8%), showing margin deterioration despite revenue growth. Intensified price competition and unfavorable project mix appear to have pressured margins. The Nursing Care & Welfare Business recorded Revenue ¥47.7B (+4.1%) and Operating Income ¥4.7B (+14.1%) with a margin of 9.8% (up 0.8pt from 9.0%), achieving double-digit profit growth and improved margin. Segment profit total of ¥79.7B less corporate expenses ¥58.5B and goodwill amortization ¥2.2B resulted in Operating Income ¥19.2B, indicating that allocation efficiency of corporate expenses significantly influences consolidated operating margin.
[Profitability] Operating margin 0.8% and Net margin 0.6% reflect an extremely low-margin structure, consistent with the characteristics of a distribution business with gross margin of 11.9%. ROE of 6.1% corresponds to annualized net income of approximately ¥17B against Equity of ¥209.0B; this is broadly flat versus historical levels but low relative to industry peers. [Cash Quality] DSO (Days Sales Outstanding) is approximately 110 days (Accounts receivable ¥683.2B ÷ annualized sales approx. ¥3,036B × 365 days), showing a lengthening trend and raising concerns about working capital efficiency. [Asset Efficiency] Total asset turnover is approximately 1.82x on an annualized basis (Revenue ¥2,276.8B annualized from 9 months ÷ Total assets ¥1,251.6B), indicating high turnover, but low net margin limits capital efficiency. [Financial Soundness] Equity Ratio is 16.7% (down 1.4pt from 18.1% YoY), indicating high leverage dependence. D/E ratio is approx. 4.99x (Interest-bearing debt approx. ¥237.1B ÷ Net assets ¥209.0B), a high level, and short-term borrowings of ¥199.1B represent the majority, resulting in a short-term debt ratio of approx. 84% (Short-term borrowings ¥199.1B ÷ Total liabilities ¥1,042.6B), making liquidity risk evident. Current ratio is 108.9% (Current assets ¥1,021.3B ÷ Current liabilities ¥938.2B), at a minimum level, and Quick ratio 93.0% (Quick assets approx. ¥873B ÷ Current liabilities ¥938.2B) is below 100%, indicating limited short-term payment capacity as evidenced by cash and deposits ¥149.1B versus short-term borrowings ¥199.1B ratio of 0.75x.
A direct cash flow statement was not disclosed, but balance sheet changes indicate cash flow dynamics. Accounts receivable increased from ¥580.0B to ¥683.2B, up ¥103.3B (+17.8%), expanding far faster than revenue growth (+3.7%), likely expanding working capital and pressuring Operating Cash Flow (OCF). Inventory increased from ¥136.0B to ¥148.7B, up ¥12.7B (+9.3%), exceeding sales growth and raising concerns over inventory turnover efficiency. Accounts payable increased from ¥601.1B to ¥691.6B, up ¥90.5B (+15.1%), which partially offset cash outflows by delaying supplier payments, but net working capital expansion persisted. Short-term borrowings rose from ¥167.6B to ¥199.1B, up ¥31.5B (+18.8%), suggesting part of working capital demand was externally financed. Cash and deposits increased only from ¥143.3B to ¥149.1B, up ¥5.7B (+4.0%), meaning large cash absorption by accounts receivable and inventory increases, limiting free cash flow generation capacity. Long-term borrowings decreased from ¥44.7B to ¥38.1B, down ¥6.6B, indicating a shift in borrowing structure toward short-term and warranting attention.
Recurring earnings depend on core medical device sales and nursing care & welfare services, with Operating Income ¥19.2B reflecting core earning power. Of non-operating income ¥6.0B, subsidy income ¥1.6B contains temporary elements but is limited in scale; dividend income ¥0.3B can be considered recurring. Extraordinary income ¥1.2B (mainly gain on sale of investment securities) boosted pre-tax profit by about 5% of ¥24.0B but did not materially distort overall profit composition. Extraordinary losses ¥0.2B were minor, having little impact on earnings quality. The gap between Operating Income and Net Income (Operating Income ¥19.2B → Net Income ¥12.8B) is driven by non-operating/extraordinary items and tax burden (effective tax rate 46.5%), with high tax burden compressing bottom-line margin. Comprehensive income of ¥8.6B was ¥4.2B below Net Income of ¥12.8B, mainly due to other comprehensive income (loss) on available-for-sale securities of -¥4.2B, indicating market valuation declines of held securities affecting shareholders’ equity quality.
Full-year guidance remains unchanged at Revenue ¥3,050.0B (YoY +5.6%), Operating Income ¥17.5B (YoY -6.7%), Ordinary Income ¥23.0B (YoY -5.1%), and Net Income ¥13.0B. Progress through Q3 was Revenue 74.7%, Operating Income 109.9%, Ordinary Income 99.7%, and Net Income 98.6%, with Operating Income progressing notably ahead of the initial plan. The company’s decision not to revise guidance likely reflects caution around Q4 (Jan–Mar) expense recognition, seasonality, and conservative assumptions on project mix. The excess progress in Operating Income may reflect mid-term SG&A restraint and earlier realization of non-operating income, but the company appears to judge upside to be limited given incorporation of corporate expenses and bonus accruals in the full-year figures.
No interim dividend was paid; full-year dividend forecast is ¥20 per share. With 22,238 thousand shares outstanding (22,237 thousand after treasury shares), annual dividend payout is approx. ¥440M, implying a Payout Ratio of about 34% against full-year Net Income forecast ¥13.0B, a sustainable level. Cash and deposits ¥149.1B are sufficient for dividend payments, but continued short-term borrowings ¥199.1B and expanding working capital mean stable free cash flow generation is a prerequisite for maintaining the dividend policy. No share buyback disclosure has been made; shareholder returns are concentrated on dividends.
Short-term debt concentration risk: Short-term borrowings ¥199.1B account for 84% of interest-bearing debt, and cash and deposits ¥149.1B (ratio vs. short-term borrowings 0.75x) do not fully cover this exposure. Deterioration in financial conditions or credit terms could make refinancing difficult and crystallize liquidity risk.
Accounts receivable collection extension risk: Rapid increase in Accounts receivable to ¥683.2B (YoY +17.8%) and DSO around 110 days suggest payment delays or lax credit controls by customers. Increased credit losses could raise allowance for doubtful accounts and worsen Operating Cash Flow.
Low-margin structure risk: Thin margins—Operating margin 0.8% and Net margin 0.6%—mean that modest SG&A increases or gross margin declines could push the company into loss. Continued price competition or rising personnel and rental costs would further expose the fragility of the earnings base.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating margin | 0.8% | 3.2% (1.7%–4.9%) | -2.3pt |
| Net margin | 0.6% | 2.7% (1.3%–6.0%) | -2.1pt |
Both Operating and Net margins are more than 2pt below industry medians, placing the company at the lower end within the trading sector.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue growth (YoY) | 3.7% | 5.0% (-5.0%–7.8%) | -1.3pt |
Revenue growth trails the industry median by 1.3pt, indicating a somewhat conservative growth pace.
※ Source: Company compilation
Although Operating Income progress at 109.9% exceeds the initial plan, the company’s decision to keep the guidance unchanged signals caution; attention should be paid to Q4 expense recognition and project mix volatility. Short-term support from SG&A restraint and non-operating income exists, but structural margin improvement has not been achieved.
Working capital expansion (Accounts receivable +17.8%, Inventory +9.3%) and DSO around 110 days hinder Operating Cash Flow creation and deepen short-term borrowing dependence. Strengthening receivables collection and improving inventory efficiency are key to capital efficiency and cash flow stability.
Reliance on short-term borrowings ¥199.1B (84% of interest-bearing debt) and a cash-to-short-term-borrowings ratio of 0.75x create liquidity constraints that elevate refinancing risk in a rising rate or tightening credit environment. Recovery of Operating Cash Flow and extension/reduction of interest-bearing debt are prerequisites for improving financial soundness.
This report is an automated earnings analysis document generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in specific securities. Industry benchmarks are reference information compiled by the firm from public financial statements. Investment decisions are the responsibility of the investor; please consult a professional advisor as necessary.